- Issue price
- ₹129per share
- Issue size
- ₹24.77 Cr19,20,000 shares
- Face value
- ₹10per equity share
- Lot size
- 1,000 sharesMin. ₹1.29 L at the upper price
- Anchor biddingTue, 2026
- OpensWed, 2026
- ClosesFri, 2026
- AllotmentTue, 2026Demat credit and Refunds same day
- ListingWed, 2026
Dates marked in the offer document as tentative. Times in IST.
Information only, not investment advice. This page provides information compiled from official offer documents for information purposes only. It is not investment advice or a recommendation to apply for, buy or sell any security. We are not a SEBI-registered investment adviser or research analyst. Investments in IPOs are subject to market risks; read the offer document carefully before investing.
Issue details
- Issue type
- Book built, fresh issue
- Fresh issue
- 19,20,000 shares (₹24.77 Cr)
- Offer for sale
- None
- Total issue
- 19,20,000 shares (₹24.77 Cr)
- Market maker portion
- 96,000 shares
- Face value
- ₹10
- Listing at
- BSE SME
Source: ProspectusUpdated
Reservation
Share of the total issue- Retail87.0%
- Market maker13.0%
| Category | Shares | Of net offer | Stated in RHP |
|---|---|---|---|
| Retail individual investors | 6,40,000 | 100.00% | 35% |
| Non-institutional investors (NII) | — | — | 15% |
| Qualified institutional buyers (QIB) | — | — | 50% |
| Anchor investors | — | — | — |
| Market maker | 96,000 | — | — |
Source: ProspectusUpdated
Lot size
Amounts at ₹129 per share| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail individual investors | 2 | 2,000 | ₹2.58 L |
Source: ProspectusUpdated
Subscription
Category-wise subscription is published by the exchanges while the issue is open. It appears here once the figures are added.
Valuation
FY 2024-25- EPS (basic)
- ₹7.19
- EPS (basic) (Period ended Sep 30, 2025)
- ₹4.73
- RoNW
- 48.85%
- NAV per share (Period ended Sep 30, 2025)
- ₹16.74
- P/E (Period ended Sep 30, 2025 (annualized))
- 27.27×
Source: ProspectusUpdated
Financials
Standalone, restated · ₹ crore| Period ended | 30 Sep 20256 months | 31 Mar 2025FY 2024-25 | 31 Mar 2024FY 2023-24 | 31 Mar 2023FY 2022-23 |
|---|---|---|---|---|
| Revenue from operations | 14.06 | 16.00 | 5.01 | 2.90 |
| Total income | 14.07 | 16.06 | 5.20 | 3.07 |
| EBITDA | 3.29 | 3.65 | 1.21 | 0.59 |
| Profit after tax | 2.33 | 2.61 | 0.82 | 0.28 |
| Net worth | 8.26 | 5.35 | 1.08 | 0.26 |
| Reserves and surplus | 2.95 | 4.86 | 0.72 | -0.10 |
| Total assets | 16.35 | 10.86 | 4.64 | 4.06 |
| Total borrowing | 4.43 | 3.86 | 2.17 | 1.97 |
FY 2024-25 vs FY 2023-24: revenue +219.7%, profit after tax +217.9%. Periods shorter than 12 months are shown as reported and are not annualised.
Source: ProspectusUpdated
About the company
The company manufactures Ayurvedic and nutraceutical products across tablets, capsules, oral liquids, powders, external preparations and oils, largely on a contract manufacturing basis. It sells domestically and to export markets, with most revenue from domestic sales and merchant exports under loan licence arrangements. Its manufacturing facility is in Sanand, Gujarat.
- Incorporated
- 2021
- Industry
- Pharmaceuticals / Ayurvedic Manufacturing
- CIN
- U24290GJ2021PLC121216
- Website
- accretionnutraveda.com
Source: ProspectusUpdated
Promoters and shareholders
| Name | Before issue | After issue |
|---|---|---|
| Mr. Mayur Popatlal Sojitra | — | — |
| Mr. Ankurkumar Shantilal Patel | — | — |
| Mr. Paraskumar Vinubhai Parmar | — | — |
| Mr. Hardik Mukundbhai Prajapati | — | — |
| Mr. Harshad Nanubhai Rathod | — | — |
| Mr. Vivek Ashok Kumar Patel | — | — |
Source: ProspectusUpdated
Objects of the issue
₹ crore| Purpose | Amount |
|---|---|
| Purchase of machinery for automation in existing manufacturing unit | 4.22 |
| Purchase of machinery for new manufacturing setup | 8.03 |
| Funding working capital requirements | 5.50 |
| General corporate purposes | 3.69 |
Source: ProspectusUpdated
Peer comparison
As listed in the offer document| Company | EPS | P/E | RoNW | NAV per share |
|---|---|---|---|---|
| Walpar Nutritions Ltd. | ₹1.06 | 3.30× | 6.24% | ₹17.05 |
| Influx Healthtech Limited | ₹4.81 | 46.99× | 11.10% | ₹38.98 |
| Accretion Nutraveda LimitedIssuer | ₹4.73 | 27.27× | 56.50% | ₹16.74 |
Source: ProspectusUpdated
Strengths and risks
Our summary of what the offer document statesStrengths
- Experienced promoters and management with hands-on involvement in operations.
- Diverse range of Ayurvedic and nutraceutical dosage forms.
- Manufacturing facility holds multiple quality and food-safety certifications.
- Revenue and profit have grown across the reported periods.
Risks
- Manufacturing operations are exposed to equipment failure, accidents and natural disasters.
- Past filing discrepancies and delayed forms with the Registrar of Companies may lead to penalties.
- Objects of the issue are not appraised by any independent agency and vendor orders are yet to be placed.
- Most revenue comes from domestic sales and merchant exports under loan licence arrangements.
- Promoters are interested in related entities with similar business objects.
Source: ProspectusUpdated
Documents
Contacts
Source: ProspectusUpdated
Allotment status
Check whether shares were allotted on the official pages below, using your PAN, application number or DP/client ID. Results appear once the basis of allotment is finalised.
- Allotment
- Refunds
- Demat credit
- Listing
Source: ProspectusUpdated
After listing
Listing price, day-one high and low, and the change from the issue price (₹129) appear here after the shares list on BSE SME.
Work out the gain or loss on allotted shares after charges and tax →
Frequently asked questions
When does the Accretion Nutraveda IPO open and close?
According to the Prospectus, the issue opens on Wednesday, 28 January 2026 and closes on Friday, 30 January 2026.
What is the Accretion Nutraveda IPO price band?
The final issue price is ₹129 per share.
What is the lot size of the Accretion Nutraveda IPO?
One lot is 1,000 shares, which is ₹1.29 L at ₹129 per share.
Where will Accretion Nutraveda shares list?
On BSE SME. The tentative listing date is Wednesday, 4 February 2026.
Who is the registrar of the issue?
KFin Technologies Limited (SEBI registration INR000000221). Allotment status is checked on the registrar's website.
How do I check the Accretion Nutraveda IPO allotment status?
The basis of allotment is expected to be finalised on Tuesday, 3 February 2026. After that, search by PAN, application number or DP/client ID on the registrar's website (KFin Technologies Limited) or the BSE website. Shares that are allotted are credited to your demat account; for an application that is not allotted, the blocked amount is released.
How will the money raised be used?
₹4.22 Cr for purchase of machinery for automation in existing manufacturing unit, ₹8.03 Cr for purchase of machinery for new manufacturing setup, ₹5.5 Cr for funding working capital requirements, ₹3.69 Cr for general corporate purposes.
Related IPOs
Also managed by Sobhagya Capital Options
- Armour Security (India)₹57Listed · 14 Jan – 19 Jan 2026
- Western Overseas Study Abroad₹56Listed · 4 Dec – 8 Dec 2025
Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.